Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2018
Pharmacy Choice - Pharmaceutical News - ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events - November 19, 2018

Pharmacy News Article

 6/21/18 - ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events

ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other EventsItem 8.01 Other Events.

On June 15, 2018, Acceleron Pharma Inc. issued a press release titled "Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association."

A copy of the press release is attached as Exhibit99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

ACCELERON PHARMA INC ExhibitEX-99.1 2 xlrn-20180620form8kex991.htm EXHIBIT 99.1 Exhibit Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association- Clinically meaningful increases in hemoglobin and reductions in red blood cell transfusion burden observed through 36 months Top-line results from the BELIEVE Phase 3 trial are on track for the middle of 2018 -CAMBRIDGE,?To view the full exhibit click here
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company's pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.

The post ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events appeared first on Market Exclusive.



© Market Exclusive 2018

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 19: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Last Chance
Nov 20: Acne Vulgaris: Comprehensive Pharmaceutical Care
Nov 26: COPD Update for Pharmacy Professionals
Nov 27: Management of Bipolar Disorder
Nov 28: A Primer to Paleo
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415